The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.

The DNA-testing company plans to sell its assets after the board rejected an acquisition proposal from Wojcicki.

This was seen recently in January 2025, when GSK (LSE/NYSE: GSK) acquired IDRx, a Boston-based biotech specializing in precision therapies for gastrointestinal stromal tumors (GIST). Initially, GSK ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

The Series B round will help the Aditum Bio-backed startup fund two mid-stage clinical trials in people with alcohol and cocaine use disorders.

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Proposed cuts to National Institutes of Health funding threaten innovation necessary to fuel advances in patient care, ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

A panel of CDC advisers, who had originally been set to meet in February, will discuss the current measles outbreak as well ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are paid.